DEVAZEPIDE (C005B-004902)

General description

Devazepide is derived from asperlicin by chemical modification and has the benzodiazepine backbone.

Application

Devazepide has been used as a cholecystokinin receptor 1 (CCK1R) antagonist in human embryonic kidney 293T cells and in human pancreatic slices.

Biochem/physiol Actions

Devazepide is a CCK1 (CCK-A) receptor antagonist and a CCK8 antagonist.

Devazepide is a cholecystokinin octapeptide (CCK1) (CCK-A) receptor antagonist. It inhibits CCK binding to peripheral-type receptor (CCK-A). Devazepide reverses the cholecystokinin octapeptide (CCK-8) based antagonism towards morphine.

Features and Benefits

This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Molecular Weight: 408.45. Empirical Formula: C₂₅H₂₀N₄O₂. Quality Level: 100. Assay: ≥. 98% (HPLC). form: powder. storage condition: desiccated. color: white to off-white. solubility: DMSO: >. 5 . mg/mL. originator: Merck &. Co., Inc., Kenilworth, NJ, U.S.. storage temp.: 2-8°C. SMILES string: CN1C(: O)[C@@H](NC(: O)c2cc3ccccc3[nH]2)N: C(c4ccccc4)c5ccccc15. InChI: 1S/C25H20N4O2/c1-29-21-14-8-6-12-18(21)22(16-9-3-2-4-10-16)27-23(25(29)31)28-24(30)20-15-17-11-5-7-13-19(17)26-20/h2-15,23,26H,1H3,(H,28,30)/t23-/m1/s1. InChI key: NFHRQQKPEBFUJK-HSZRJFAPSA-N. Pictograms: GHS06. Signal Word: Danger. Hazard Statements: H300. Precautionary Statements: P264 - P270 - P301 + P310 - P405 - P501. Hazard Classifications: Acute Tox. 1 Oral. Storage Class Code: 6.1A - Combustible, acute toxic Cat. 1 and 2 / very toxic hazardous materials. WGK: WGK 3. Flash Point(F): Not applicable. Flash Point(C): Not applicable.